Skip to content
The Nexus
DossierENTITY

Edgewise Therapeutics

Coverage of Edgewise Therapeutics in the Nexus archive.

Earliest in view: Jun 1 · 12:31 UTCMost recent: Jun 1 · 12:31 UTC
Co-mentioned in this coverage
Servierorganization1sevasemtentopic1Becker muscular dystrophytopic1Duchenne muscular dystrophytopic1
Recent coverage
  • HEALTHJun 1 · 12:31 UTCSTAT NEWS
    STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug

    French pharma company Servier will acquire Edgewise Therapeutics’ muscular dystrophy business in a deal worth up to $2.65 billion. The acquisition centers on Edgewise’s sevasemten, an oral drug in pivotal trials for Becker muscular dystrophy and Phase 2 trials for Duchenne muscular dystrophy.

Edgewise Therapeutics · Dossier · The Nexus